Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 164-171 , Summer 2009

Palliative Care for the Patient With Mesothelioma

  • Janet L. Abrahm, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Janet L. Abrahm, MD, Dana Farber Cancer Institute, Department of Psychosocial Oncology and Palliative Care, 44 Binney Street, Shields-Warren 420, Boston, MA 02115

References 

  1. Muers MF, Shephens RJ, Fisher P, et al. Active symptom with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): A multicentre randomized trial. Lancet. 2008;371:1685–1694
  2. Abrahm JL. A Physician's Guide to Pain and Symptom Management in Cancer Patients. [ed 2]. Baltimore, MD: Johns Hopkins University Press; 2005;
  3. Miaskowski C, Cleary J, Burney R, et al. Guideline for the Management of Cancer Pain in Adults and Children, APS Clinical Practice Guidelines Series (Number 3). Glenview, IL: American Pain Society; 2005;
  4. Smith TJ, Coyne PJ. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients. J Palliat Med. 2005;8:736–742
  5. Breivik H. Local anaesthetic blocks and epidurals. In:  McMahon SB,  Koltzenberg M editor. Wall and Melzack's Textbook of Pain. (ed 5). Philadelphia, PA: Elsevier/Churchill Livingstone; 2006;p. 507
  6. Blinderman CD, Fowler B, Abrahm JL. Pain management and antiemetic therapy in hematologic disorders. In:  Hoffman R,  Benz EZ,  Shattil SJ, et al. editor. Hematology, Basic Principles and Practice. Philadelphia, PA: Elsevier/Churchill Livingstone; 2009;p. 1501–1515
  7. Foley KM. Management of cancer pain. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: Principles and Practice of Oncology. (ed 7). Philadelphia, PA: Lippincott Williams & Wilkins; 2005;p. 2615
  8. Davis MP, Walsh D. Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer. 2001;9:73–83
  9. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: Reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005;14:747–753
  10. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7:39–46
  11. Block SD. Psychological issues in end-of-life care. J Palliat Med. 2006;9:751–772
  12. Cassell E. The Nature of Suffering and the Goals of Medicine. (ed 2). New York, NY: Oxford University Press; 2004;
  13. Block SD, Billings JA. Patient requests to hasten death: Evaluation and management in terminal care. Arch Intern Med. 1994;154:2039–2047
  14. Byock I. Dying Well: The Prospect of Growth at the End of Life. New York, NY: Riverhead Press; 1997;
  15. Balboni TA, Vanderwerker LC, Block SD, et al. Religiousness and spiritual support among advanced cancer patients and associations with end-of-life treatment preferences and quality of life. J Clin Oncol. 2007;26:555–560
  16. Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. J Am Med Assoc. 2008;300:1665–1673
  17. Faulkner A, Maguire P. Talking to Cancer Patients and Their Relatives. Oxford: Oxford Medical Publishing; 1994;
  18. Abrahm JL. Specialized care of the terminally ill. In:  DeVita VT,  Lawrence TS,  Rosenberg SA editor. DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2008;p. 2830–2846
  19. Casarett D, Kutner JS, Abrahm J. Life after death: A practical approach to grief and bereavement. Ann Intern Med. 2001;134:208–215

PII: S1043-0679(09)00070-7

doi: 10.1053/j.semtcvs.2009.06.006

Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 164-171 , Summer 2009

Article Tools